John Militello - 18 Apr 2022 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)

Role
VP, Principal Accounting Officer and Interim Principal Financial Officer
Signature
/s/ Martin Wilson, as attorney-in-fact for John Militello
Issuer symbol
RCKT
Transactions as of
18 Apr 2022
Net transactions value
$0
Form type
4
Filing time
20 Apr 2022, 16:06:34 UTC
Previous filing
16 Feb 2022
Next filing
16 Aug 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RCKT Stock Option (Right to Buy) Award $0 +28,910 $0.000000 28,910 18 Apr 2022 Common Stock 28,910 $13.12 Direct F1
transaction RCKT Restricted Stock Units Award $0 +19,054 $0.000000 19,054 18 Apr 2022 Common Stock 19,054 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option represents a right to purchase a total of 28,910 shares of the Issuer's common stock, one-third (1/3) of which will become fully vested and exercisable on April 18, 2023, with the remaining shares vesting in equal quarterly installments over the following two years.
F2 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3 One-third (1/3) of such restricted stock units will become fully vested and exercisable on April 18, 2023, with the remaining shares vesting in equal quarterly installments over the following two years.

Remarks:

VP, Principal Accounting Officer and Interim Principal Financial Officer